Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met the primary endpoint showing superior improvements in key cardiometabolic markers in patients with type 2 diabetes compared to Astrazeneca plc’s SGLT2 inhibitor, Farxiga (dapagliflozin), in a head-to-head phase III trial.
In an effort to identify stronger and safer α-glucosidase inhibitors, researchers at the Chinese Academy of Sciences prepared a series of diarylpentane derivatives, the most promising of which, [I], reversibly inhibited α-glucosidase with an IC50 of 18 µM.
In a phase II study, Novo Nordisk A/S’s amycretin reduced the weight of type 2 diabetes patients by 14.5% in 36 weeks, a statistically significant loss. The results also produced reduced hemoglobin A1C levels, an average of blood glucose that is used to monitor blood sugar control, below 7% in up to 89.1% of the participants.
Pfizer Inc. has divulged gastric inhibitory polypeptide receptor (GIPR) antagonists reported to be useful for the treatment of type 2 diabetes and obesity.
Mwyngil Therapeutics Inc. has in-licensed several lead GPR75 modulator molecules and a proprietary cell-surface discovery platform from Expert Systems Inc.
Adocia SA is looking to further apply its Biochaperone formulation technology to metabolic disorders, Olivier Soula, Adocia co-founder and CEO told BioWorld, the firmhaving recently gained positive top-line phase III results of Tonghua Dongbao Pharmaceutical Co. Ltd.’s THDB-0206 injection (Biochaperone Lispro) in diabetes patients in China.
Adocia SA is looking to further apply its Biochaperone formulation technology to metabolic disorders, Olivier Soula, Adocia co-founder and CEO told BioWorld, the firmhaving recently gained positive top-line phase III results of Tonghua Dongbao Pharmaceutical Co. Ltd.’s THDB-0206 injection (Biochaperone Lispro) in diabetes patients in China.
Activating the glucagon-like peptide 1 receptor (GLP-1R) is the mechanism of action of most drugs currently used to treat obesity and type 2 diabetes. To enhance efficacy and reduce side effects, many groups have been developing double or triple agonists that, at the same time, also stimulate the receptors for glucagon (GCG) or glucose-dependent insulinotropic peptide (GIP).
Among severe insulin-deficient diabetes patients, 12 weeks of 100-mg, once-daily dosing of Biomea Fusion Inc.’s icovamenib lowered hemoglobin A1c by 1.8% from placebo at the 52-week timepoint, an increased benefit over and above what was seen at 26 weeks.
